Tenders Are Invited For “Delivery Of Medicinal Products For 2025, Granted Pursuant To Ordinance No. 34 Of 25.11.2005 On The Procedure For Paying By The State Budget Of Treatment Of Bulgarian Citizens For Diseases, Outside The Scope Of Compulsory Health Insurance, For The Treatment Of Patients With Hiv/Aids, Sep, Mental And Behavioral Disorders Due Emtricitabine/ Tenofovir Disoproxil
Tenders Are Invited For “Delivery Of Medicinal Products For 2025, Granted Pursuant To Ordinance No. 34 Of 25.11.2005 On The Procedure For Paying By The State Budget Of Treatment Of Bulgarian Citizens For Diseases, Outside The Scope Of Compulsory Health Insurance, For The Treatment Of Patients With Hiv/Aids, Sep, Mental And Behavioral Disorders Due Emtricitabine/ Tenofovir Disoproxil
The Present Public Procurement Is Subject: “Delivery Of Medicinal Products For 2025, Granted Pursuant To Ordinance No. 34 Of 25.11.2005 On The Order For Payment By The State Budget Of Treatment Of Bulgarian Citizens For Diseases, Outside The Scope Of Compulsory Health Insurance, For The Treatment Of Patients With Hiv/Aids, Tuberculosis And Behaviors Addiction - Delivery Of Emtricitabine/ Tenofovir Disoproxil By Decision No. F631841/31.03.2025, The Ministry Of Health Opened A Procedure With The Subject: “Delivery Of Medicinal Products For 2025, Granted In Accordance With Ordinance No. 34 Of 25.11.2005 On The Order For Payment By The State Budget Of The Bulgarian Citizens, Outside The Mandatory Health Insurance Mental And Behavioral Disorders Due To The Use Of Opioids, Dependence Syndrome, Including 23 (Twenty-Three) Self-Separate Positions (00080-2025-0006). On The Grounds Of Art. 110, Para. 1, Item 1 Of The Public Procurement Act, Due To The Lack Of Tenders Submitted, The Procedure Was Terminated In Lot No 8 Emtricitabine/Tenofovir Disoproxil. The Antiretroviral Medicinal Product Emtricitabine/Tenofovir Disoproxil In The Termination Position Is Required For The Therapeutic Regimens Of The Patients Prescribed Because Of Its Specific Therapeutic Indications And Pharmacological Characteristics. In 2025, For Treatment With Emtricitabine/Tenofovir Disoproxil, 603 Patients Were Provided, Respectively 7 236 Packs (217 080 Tablets).
We takes all possible care for accurate & authentic tender information, however Users are requested to refer Original source of Tender Notice / Tender Document published by Tender Issuing Agency before taking any call regarding this tender.